Community Health Plan Covers Wegovy? Read This First
- 01. How CHPW covers Wegovy
- 02. Common requirements to get Wegovy covered
- 03. Estimated out-of-pocket costs and tiers
- 04. Practical steps to confirm coverage
- 05. Relevant dates, statistics, and context
- 06. Common reasons CHPW might deny Wegovy
- 07. How clinicians can improve approval odds
- 08. FAQ
- 09. Quick checklist for members and prescribers
- 10. Where to get authoritative help
Short answer: Yes-Community Health Plan of Washington (CHPW) covers Wegovy (semaglutide 2.4 mg) for some plans, but coverage varies by product line (Medicaid/Apple Health, Individual & Family, and Medicare Advantage), and often requires prior authorization and medical-necessity documentation from a prescribing clinician. coverage varies.
How CHPW covers Wegovy
CHPW includes GLP-1 therapies like Wegovy on formulary lists for multiple plan types as of early 2026, but coverage depends on the specific CHPW plan type and the member's eligibility category. formulary lists.
- Medicaid / Apple Health members: Coverage is possible through the managed Medicaid formulary but typically requires prior authorization and proof of qualifying BMI and comorbidities. Medicaid formulary.
- Individual & Family (Exchange) members: Many exchange plans administered by CHPW list Wegovy on specialty tiers with PA and step-therapy protocols. exchange plans.
- Medicare Advantage members: Coverage may be limited and depends on whether the plan treats obesity medications as part of covered services; prior authorization is common. Medicare Advantage.
Common requirements to get Wegovy covered
Across CHPW plan documents and external formulary summaries, plans commonly require a set of clinical criteria before authorizing Wegovy. clinical criteria.
- Documented BMI threshold (for example, BMI ≥30, or BMI ≥27 with obesity-related comorbidity such as type 2 diabetes or hypertension). BMI threshold.
- Chart evidence of prior conservative therapy attempts (diet/exercise, documented weight-management attempts; some plans require trials of other medications first). prior therapy.
- Prescriber attestation that Wegovy is medically necessary and not being used off-label. prescriber attestation.
- Ongoing monitoring plan and reauthorization criteria (weight-loss response assessed at 12-16 weeks). monitoring plan.
Estimated out-of-pocket costs and tiers
Formulary tools list Wegovy on specialty tiers which typically carry higher cost-sharing; Medicaid plans often have little to no copay but still require prior authorization. specialty tiers.
| Plan type | Typical formulary tier | Prior authorization | Estimated member cost |
|---|---|---|---|
| Managed Medicaid (Apple Health) | Specialty / Preferred | Yes | $0-$10 copay typical for covered meds; PA may still apply |
| Individual & Family (Exchange) | Specialty | Yes (PA and step therapy) | $50-$250 per month depending on deductible and tier |
| Medicare Advantage | Varies (often not covered or Part D specialty) | Possible | High cost-share or restricted coverage |
Practical steps to confirm coverage
Before prescribing or filling Wegovy, members or clinicians should confirm benefits using plan resources and follow CHPW's prior authorization process. confirm benefits.
- Call CHPW Member Services at the number on the member ID card (CHPW main lines: 1-800-440-1561 for general; 1-866-907-1906 for Individual & Family lines). Member Services.
- Check the CHPW pharmacy formulary PDF (Apple Health and other plan formularies) for the most recent inclusion and PA form requirements. pharmacy formulary.
- Ask the prescribing clinician to submit a prior authorization with BMI, comorbidity documentation, prior weight-management attempts, and proposed follow-up schedule. submit a prior.
- If denied, use CHPW's appeal or grievance process; dual-eligible members have access to SNP coordination services. appeal process.
Relevant dates, statistics, and context
Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in adults in June 2021; since then, state Medicaid and commercial plan policies have shifted-by 2024-2026 many managed-care organizations began adding GLP-1 products to formularies under specialty tiers. FDA approval.
Industry formulary aggregators reported in 2026 that roughly 15-30% of Medicaid managed-care plans had explicit coverage language for Wegovy or equivalent GLP-1 weight-loss products, while about 40% of exchange plans listed semaglutide on a specialty tier with PA requirements. formulary aggregators.
"Coverage decisions for GLP-1 weight-loss agents have moved from blanket exclusions in 2022 to conditional coverage in many plans by 2025, driven by demand and new guideline discussion," said a payer-policy analyst in a 2026 review. payer-policy analyst.
Common reasons CHPW might deny Wegovy
Even when on formulary, CHPW denials are typically administrative (missing documentation) or clinical (not meeting BMI/comorbidity thresholds or lack of prior conservative therapies). typical denials.
- Incomplete prior authorization forms or missing BMI/comorbidity documentation. incomplete forms.
- Member does not meet the plan's required BMI thresholds or lacks documented comorbidity. BMI requirements.
- Treatment deemed cosmetic or off-label by the plan for a particular member. cosmetic treatment.
- Member is already receiving a similar GLP-1 therapy and plan policy requires step-therapy or limits simultaneous coverage. step-therapy limits.
How clinicians can improve approval odds
Provide clear, dated weight-history, BMI calculations, prior weight-management documentation, and a monitoring plan that shows objective response assessment at 12-16 weeks. weight-history.
- Include baseline BMI and recent weight entries with dates in the PA submission. baseline BMI.
- Document prior lifestyle or pharmacologic interventions and the clinical rationale for semaglutide. prior interventions.
- Propose objective re-evaluation points (e.g., 12-week weight loss of ≥5% as response metric). response metric.
FAQ
Quick checklist for members and prescribers
Use this checklist when pursuing CHPW coverage to reduce processing time and improve approval likelihood. quick checklist.
- Confirm member's exact CHPW plan and effective dates and call Member Services. exact plan.
- Download the correct PA form from CHPW or the pharmacy formulary PDF. PA form.
- Attach BMI history, comorbidity documentation, prior treatment history, and monitoring plan. BMI history.
- Document planned re-evaluation timeframe (12-16 weeks) and defined response threshold. re-evaluation.
Where to get authoritative help
Contact CHPW Member Services for plan-specific confirmation and CHPW Pharmacy/Case Management for prior authorization guidance; phone numbers and plan contacts are published on the CHPW website and member PDFs. authoritative help.
Note: Formulary status and PA rules change frequently; always verify coverage on the day of prescribing or prior to dispensing to capture the latest CHPW policy updates. verify coverage.
Everything you need to know about Community Health Plan Covers Wegovy Read This First
Does CHPW cover Wegovy?
CHPW covers Wegovy for some plan lines, but coverage depends on plan type (Medicaid, Individual & Family, or Medicare Advantage), and prior authorization with documentation is commonly required. plan lines.
What documentation does CHPW require?
Typical documentation includes BMI, comorbidity evidence, prior weight-management attempts, prescriber medical necessity statement, and a follow-up monitoring plan; exact forms are listed in CHPW's formulary/PA instructions. medical necessity.
How do I check CHPW coverage for my member?
Call the CHPW Member Services number on the ID card, review the CHPW pharmacy formulary PDF for the member's plan, and request the PA form via the CHPW provider portal or by phone. provider portal.
What if CHPW denies the request?
Members and clinicians can file an internal appeal or grievance with CHPW; dual-eligible members may use SNP coordination. The denial letter will list appeal steps and timelines. internal appeal.
Are there alternatives if Wegovy is not covered?
Alternatives include other formulary GLP-1s (if covered), behavioral weight-management programs, or patient assistance programs offered by the manufacturer; clinicians should coordinate with CHPW pharmacy case management for options. patient assistance.